Hematology NewsR-CHOP looks viable as first line in follicular lymphomaNovember 15, 2018Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
Hematology NewsBortezomib may unlock resistance in WM with mutationsNovember 15, 2018Indolent LymphomaLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsRelapsed MCL: Options for treatmentNovember 15, 2018Mantle Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsCLL: The initial work-upNovember 13, 2018CLLIndolent LymphomaLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsFDA puts selinexor on fast track for DLBCLNovember 8, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology TimesSelinexor on fast track for DLBCLNovember 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma
Hematology TimesCombo appears safe, active in rel/ref NHLNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology TimesSandoz won’t seek U.S. approval for rituximab biosimilarNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsSandoz halts pursuit of U.S. approval for rituximab biosimilarNovember 5, 2018CLLLymphoma & Plasma Cell DisordersIndolent LymphomaFollicular LymphomaB Cell Lymphoma
Hematology NewsCheckpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
The Journal of Community and Supportive OncologyCollaboration is key to bridging the AYA cancer care divideOctober 31, 2018Patient & Survivor CarePediatricsB Cell Lymphoma
The Journal of Community and Supportive OncologyGame changers in pediatric cancerOctober 31, 2018Patient & Survivor CarePediatricsB Cell Lymphoma
Hematology NewsLine complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphomaOctober 25, 2018Aggressive LymphomasThrombosisLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsFirst-line bortezomib prolongs survival in MCLOctober 25, 2018Mantle Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology TimesCombo can prolong overall survival in MCLOctober 25, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma
